4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors

US10975062B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Michael H. Rabinowitz · San Diego, US
• Mark D. Rosen · San Diego, US
• Kyle T. Tarantino · Princeton, US
• Hariharan Venkatesan · San Diego, US

Key dates

• Filing date: Apr 1, 2019
• Grant date: Apr 13, 2021
• Expiry date: Apr 1, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.